Toxicological Significance of Mechanism-Based Inactivation of Cytochrome P450 Enzymes by Drugs

REFERENCES

• Agarwal A., Balla J., Alam J., Croatt A. J., Nath K. A. Induction of heme oxygenase in toxic renal injury: A protective role in cisplatin nephrotoxicity in the rat. Kidney Int. 1995; 48: 1298–1307
   PubMed Web of Science ®Google Scholar
• Agarwal A., Nick H. S. Renal response to tissue injury: Lessons from heme oxygenase-1 GeneAblation and expression. J. Am. Soc. Nephrol. 2000; 11: 965–973
   PubMed Web of Science ®Google Scholar
• Albano E. Free radical mechanisms in immune reactions associated with alcoholic liver disease. Free Radic. Biol. Med. 2002; 32: 110–114
   PubMed Web of Science ®Google Scholar
• Anderson J. R., Nawarskas J. J. Cardiovascular drug–drug interactions. Cardiol. Clin. 2001; 19: 215–234
   PubMedGoogle Scholar
• Augusto O., Beilan H. S., Ortiz de Montellano P. R. The catalytic mechanism of cytochrome P-450. Spin-trapping evidence for one-electron substrate oxidation. J. Biol. Chem. 1982; 257: 11288–11295
   PubMed Web of Science ®Google Scholar
• Augusto O., Kunze K. L., Ortiz de Montellano P. R. N-Phenylprotoporphyrin IX formation in the hemoglobin-phenylhydrazine reaction. Evidence for a protein-stabilized iron-phenyl intermediate. J. Biol. Chem. 1982; 257: 6231–6241
   PubMed Web of Science ®Google Scholar
• Awad J. A., Horn J. L., Roberts L. J., 2nd, Franks J. J. Demonstration of halothane-induced hepatic lipid peroxidation in rats by quantification of F2-isoprostanes. Anesthesiology 1996; 84: 910–916
   PubMed Web of Science ®Google Scholar
• Baker M. T., Vasquez M. T., Chiang C. K. Evidence for the stability and cytochrome P450 specificity of the phenobarbital-induced reductive halothane-cytochrome P450 complex formed in rat hepatic microsomes. Biochem. Pharmacol. 1991; 41: 1691–1699
   PubMed Web of Science ®Google Scholar
• Baliga R., Zhang Z., Baliga M., Ueda N., Shah S. V. In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity. Kidney Int. 1998a; 53: 394–401
   PubMed Web of Science ®Google Scholar
• Baliga R., Zhang Z., Baliga M., Ueda N., Shah S. V. Role of cytochrome P-450 as a source of catalytic iron in cisplatin-induced nephrotoxicity. Kidney Int. 1998b; 54: 1562–1569
   PubMed Web of Science ®Google Scholar
• Beaune P., Dansette P. M., Mansuy D., Kiffel L., Finck M., Amar C., Leroux J. P., Homberg J. C. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc. Natl. Acad. Sci. U.S.A. 1987; 84: 551–555
   PubMed Web of Science ®Google Scholar
• Beaune P., Pessayre D., Dansette P., Mansuy D., Manns M. Autoantibodies against cytochromes P450: Role in human diseases. Adv. Pharmacol. 1994; 30: 199–245
   PubMedGoogle Scholar
• Beaune P. H., Lecoeur S. Immunotoxicology of the liver: Adverse reactions to drugs. J. Hepatol. 1997; 26: 37–42
   Web of Science ®Google Scholar
• Bedford T. A., Rowbotham D. J. Cisapride. Drug interactions of clinical significance. Drug Saf. 1996; 15: 167–175
   PubMed Web of Science ®Google Scholar
• Bellingham R. M., Gibbs A. H., de Matteis F., Lian L. Y., Roberts G. C. Determination of the structure of an N-substituted protoporphyrin isolated from the livers of griseofulvin-fed mice. Biochem. J. 1995; 307: 505–512
   Google Scholar
• Belloc C., Gauffre A., Andre C., Beaune P. H. Epitope mapping of human CYP1A2 in dihydralazine-induced autoimmune hepatitis. Pharmacogenetics 1997; 7: 181–186
   PubMedGoogle Scholar
• Bertelsen K. M., Venkatakrishnan K., Von Moltke L. L., Obach R. S., Greenblatt D. J. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: Comparison with fluoxetine and quinidine. Drug Metab. Dispos. 2003; 31: 289–293
   PubMed Web of Science ®Google Scholar
• Bocker R. H., Guengerich F. P. Oxidation of 4-aryl-and 4-alkyl-substituted 2,6-dimethyl-3,5-bis(alkoxycarbonyl)-1,4-dihydropyridines by human liver microsomes and immunochemical evidence for the involvement of a form of cytochrome P-450. J. Med. Chem. 1986; 29: 1596–1603
   PubMed Web of Science ®Google Scholar
• Bornheim L. M., Underwood M. C., Caldera P., Rettie A. E., Trager W. F., Wrighton S. A., Correia M. A. Inactivation of multiple hepatic cytochrome P-450 isozymes in rats by allylisopropylacetamide: mechanistic implications. Mol. Pharmacol. 1987; 32: 299–308
   PubMedGoogle Scholar
• Bourdi M., Chen W., Peter R. M., Martin J. L., Buters J. T., Nelson S. D., Pohl L. R. Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis. Chem. Res. Toxicol. 1996; 9: 1159–1166
   PubMed Web of Science ®Google Scholar
• Bourdi M., Larrey D., Nataf J., Bernuau J., Pessayre D., Iwasaki M., Guengerich F. P., Beaune P. H. Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450IA2. A specific marker of dihydralazine-induced hepatitis. J. Clin. Invest. 1990; 85: 1967–1973
   PubMed Web of Science ®Google Scholar
• Bourdi M., Tinel M., Beaune P. H., Pessayre D. Interactions of dihydralazine with cytochromes P4501A: A possible explanation for the appearance of anti-cytochrome P4501A2 autoantibodies. Mol. Pharmacol. 1994; 45: 1287–1295
   PubMed Web of Science ®Google Scholar
• Bourrie M., Meunier V., Berger Y., Fabre G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J. Pharmacol. Exp. Ther. 1996; 277: 321–332
   PubMed Web of Science ®Google Scholar
• Brueggemeier R. W., Hackett J. C., Diaz-Cruz E. S. Aromatase inhibitors in the treatment of breast cancer. Endocr. Rev. 2005; 26: 331–345
   PubMed Web of Science ®Google Scholar
• Buzaleh A. M., del Camen Martinez M., del Carmen Batlle A. M. Relevance of cytochrome P450 levels in the actions of enflurane and isoflurane in mice: studies on the haem pathway. Clin. Exp. Pharmacol. Physiol. 2000; 27: 796–800
   Google Scholar
• Chan W. K., Sui Z., Ortiz de Montellano P. R. Determinants of protein modification versus heme alkylation: Inactivation of cytochrome P450 1A1 by 1-ethynylpyrene and phenylacetylene. Chem. Res. Toxicol. 1993; 6: 38–45
   PubMed Web of Science ®Google Scholar
• Chang T. K., Gonzalez F. J., Waxman D. J. Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch. Biochem. Biophys. 1994; 311: 437–442
   PubMed Web of Science ®Google Scholar
• Cheitlin M. D., Hutter A. M., Jr., Brindis R. G., Ganz P., Kaul S., Russell R. O., Jr., Zusman R. M. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J. Am. Coll. Cardiol. 1999; 33: 273–282
   PubMed Web of Science ®Google Scholar
• Chen Q., Ngui J. S., Doss G. A., Wang R. W., Cai X., DiNinno F. P., Blizzard T. A., Hammond M. L., Stearns R. A., Evans D. C., Baillie T. A., Tang W. Cytochrome P450 3A4-mediated bioactivation of raloxifene: Irreversible enzyme inhibition and thiol adduct formation. Chem. Res. Toxicol. 2002; 15: 907–914
   PubMed Web of Science ®Google Scholar
• Chiba M., Nishime J. A., Lin J. H. Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor. J. Pharmacol. Exp. Ther. 1995; 275: 1527–1534
   PubMed Web of Science ®Google Scholar
• Christians U., Jacobsen W., Floren L. C. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?. Pharmacol. Ther. 1998; 80: 1–34
   PubMed Web of Science ®Google Scholar
• Clot P., Bellomo G., Tabone M., Arico S., Albano E. Detection of antibodies against proteins modified by hydroxyethyl free radicals in patients with alcoholic cirrhosis. Gastroenterology 1995; 108: 201–207
   Google Scholar
• Cole S. P., Whitney R. A., Marks G. S. Ferrochelatase-inhibitory and porphyrin-inducing properties of 3,5-diethoxy-carbonyl-1, 4-dihydro-2,4,6-trimethylpyridine and its analogues in chick embryo liver cells. Mol. Pharmacol. 1981; 20: 395–403
   PubMed Web of Science ®Google Scholar
• Correia M. A., Davoll S. H., Wrighton S. A., Thomas P. E. Degradation of rat liver cytochromes P450 3A after their inactivation by 3,5-dicarbethoxy-2,6-dimethyl-4-ethyl-1,4-dihydropyridine: Characterization of the proteolytic system. Arch. Biochem. Biophys. 1992; 297: 228–238
   PubMed Web of Science ®Google Scholar
• Correia M. A., Decker C., Sugiyama K., Caldera P., Bornheim L., Wrighton S. A., Rettie A. E., Trager W. F. Degradation of rat hepatic cytochrome P-450 heme by 3,5-dicarbethoxy-2,6-dimethyl-4-ethyl-1,4-dihydropyridine to irreversibly bound protein adducts. Arch. Biochem. Biophys. 1987; 258: 436–451
   PubMed Web of Science ®Google Scholar
• Correia M. A., Oritz de Montellano P. R. Inhibition of cytochrome P450 enzymes. Cytochrome P450: Structure, mechanism, and biochemistry, 3rd ed., P. R. Oritz de Montellano. Kluwer, New York 2005; 247–322
   Google Scholar
• Correia M. A., Yao K., Wrighton S. A., Waxman D. J., Rettie A. E. Differential apoprotein loss of rat liver cytochromes P450 after their inactivation by 3,5-dicarbethoxy-2,6-dimethyl-4-ethyl-1,4-dihydropyridine: A case for distinct proteolytic mechanisms?. Arch. Biochem. Biophys. 1992; 294: 493–503
   PubMed Web of Science ®Google Scholar
• Corsini A., Bellosta S., Baetta R., Fumagalli R., Paoletti R., Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther. 1999; 84: 413–428
   PubMed Web of Science ®Google Scholar
• Cuttle L., Munns A. J., Hogg N. A., Scott J. R., Hooper W. D., Dickinson R. G., Gillam E. M. Phenytoin metabolism by human cytochrome P450: involvement of P450 3A and 2C forms in secondary metabolism and drug-protein adduct formation. Drug Metab. Dispos. 2000; 28: 945–950
   PubMed Web of Science ®Google Scholar
• Dansette P. M., Bertho G., Mansuy D. First evidence that cytochrome P450 may catalyze both S-oxidation and epoxidation of thiophene derivatives. Biochem. Biophys. Res. Commun. 2005; 338: 450–455
   PubMed Web of Science ®Google Scholar
• Davies R., Schuurman A., Barker C. R., Clothier B., Chernova T., Higginson F. M., Judah D. J., Dinsdale D., Edwards R. E., Greaves P., Gant T. W., Smith A. G. Hepatic gene expression in protoporphyic Fech mice is associated with cholestatic injury but not a marked depletion of the heme regulatory pool. Am. J. Pathol. 2005; 166: 1041–1053
   Google Scholar
• De Groot H., Noll T. Halothane hepatotoxicity: Relation between metabolic activation, hypoxia, covalent binding, lipid peroxidation and liver cell damage. Hepatology 1983; 3: 601–606
   PubMed Web of Science ®Google Scholar
• De Matteis F. Toxicological aspects of liver heme biosynthesis. Semin. Hematol. 1988; 25: 321–329
   Google Scholar
• De Matteis F., Gibbs A. H. Drug-induced conversion of liver haem into modified porphyrins. Evidence for two classes of products. Biochem. J. 1980; 187: 285–288
   PubMed Web of Science ®Google Scholar
• De Matteis F., Gibbs A. H., Farmer P. B., Lamb J. H. Liver production of N-alkylated porphyrins caused in mice by treatment with substituted dihydropyridines. Evidence that the alkyl group on the pyrrole nitrogen atom originates from the drug. FEBS Lett. 1981; 129: 328–331
   PubMed Web of Science ®Google Scholar
• De Matteis F., Gibbs A. H., Holley A. E. Occurrence and biological properties of N-methyl protoporphyrin. Ann. NY Acad. Sci. 1987; 514: 30–40
   Google Scholar
• De Matteis F., Gibbs A. H., Martin S. R., Milek R. L. Labelling in vivo and chirality of griseofulvin-derived N-alkylated protoporphyrins. Biochem. J. 1991; 280: 813–816
   Google Scholar
• De Matteis F., Gibbs A. H., Smith A. G. Inhibition of protohaem ferro-lyase by N-substituted porphyrins. Structural requirements for the inhibitory effect. Biochem. J. 1980; 189: 645–648
   PubMed Web of Science ®Google Scholar
• de Matteis F., Hollands C., Gibbs A. H., De Sa N., Rizzardini M. Inactivation of cytochrome P-450 and production of N-alkylated porphyrins caused in isolated hepatocytes by substituted dihydropyridines. Structural requirements for loss of haem and alkylation of the pyrrole nitrogen atom. FEBS Lett. 1982; 145: 87–92
   PubMed Web of Science ®Google Scholar
• De Matteis F., Marks G. S. Cytochrome P450 and its interactions with the heme biosynthetic pathway. Can. J. Physiol. Pharmacol. 1996; 74: 1–8
   PubMed Web of Science ®Google Scholar
• Denk H., Eckerstorfer R., Talcott R. E., Schenkman J. B. Alteration of hepatic microsomal enzymes by griseofulvin treatment of mice. Biochem. Pharmacol. 1977; 26: 1125–1130
   PubMed Web of Science ®Google Scholar
• Desta Z., Kerbusch T., Flockhart D. A. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin. Pharmacol. Ther. 1999; 65: 10–20
   PubMed Web of Science ®Google Scholar
• DeVane C. L., Markowitz J. S., Hardesty S. J., Mundy S., Gill H. S. Fluvoxamine-induced theophylline toxicity. Am. J. Psychiatry. 1997; 154: 1317–1318
   Google Scholar
• Dresser G. K., Spence J. D., Bailey D. G. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin. Pharmacokinet. 2000; 38: 41–57
   PubMed Web of Science ®Google Scholar
• Eagling V. A., Tjia J. F., Back D. J. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br. J. Clin. Pharmacol. 1998; 45: 107–114
   PubMed Web of Science ®Google Scholar
• Ekins S., VandenBranden M., Ring B. J., Wrighton S. A. Examination of purported probes of human CYP2B6. Pharmacogenetics 1997; 7: 165–179
   PubMedGoogle Scholar
• Eliasson E., Kenna J. G. Cytochrome P450 2E1 is a cell surface autoantigen in halothane hepatitis. Mol. Pharmacol. 1996; 50: 573–582
   PubMed Web of Science ®Google Scholar
• Eliasson E., Stal P., Oksanen A., Lytton S. Expression of autoantibodies to specific cytochromes P450 in a case of disulfiram hepatitis. J. Hepatol. 1998; 29: 819–825
   PubMed Web of Science ®Google Scholar
• Ernest C. S., 2nd, Hall S. D., Jones D. R. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J. Pharmacol. Exp. Ther. 2005; 312: 583–591
   PubMed Web of Science ®Google Scholar
• Ferrara R., Tolando R., King L. J., Manno M. Cytochrome P450 inactivation during reductive metabolism of 1,1-dichloro-2,2,2-trifluoroethane (HCFC-123) by phenobarbital-and pyridine-induced rat liver microsomes. Toxicol. Appl. Pharmacol. 1997; 143: 420–428
   PubMed Web of Science ®Google Scholar
• Gamble J. T., Dailey H. A., Marks G. S. N-Methylprotoporphyrin is a more potent inhibitor of recombinant human than of recombinant chicken ferrochelatase. Drug Metab. Dispos. 2000; 28: 373–375
   Google Scholar
• Gamble J. T., Nakatsu K., Marks G. S. Comparison of the formation of N-alkylprotoporphyrin IX after interaction of porphyrinogenic xenobiotics with single cDNA-expressed human P450 enzymes in microsomes prepared from baculovirus-infected insect cells and human lymphoblastoid cell lines. Drug Metab. Dispos. 2003; 31: 202–205
   Google Scholar
• Gant T. W., Baus P. R., Clothier B., Riley J., Davies R., Judah D. J., Edwards R. E., George E., Greaves P., Smith A. G. Gene expression profiles associated with inflammation, fibrosis, and cholestasis in mouse liver after griseofulvin. EHP Toxicogenomics 2003; 111: 37–43
   Google Scholar
• Gorman N., Ross K. L., Walton H. S., Bement W. J., Szakacs J. G., Gerhard G. S., Dalton T. P., Nebert D. W., Eisenstein R. S., Sinclair J. F., Sinclair P. R. Uroporphyria in mice: Thresholds for hepatic CYP1A2 and iron. Hepatology 2002; 35: 912–921
   Google Scholar
• Griem P., Wulferink M., Sachs B., Gonzalez J. B., Gleichmann E. Allergic and autoimmune reactions to xenobiotics: How do they arise?. Immunol. Today 1998; 19: 133–141
   PubMedGoogle Scholar
• Gruchalla R. S. Drug metabolism, danger signals, and drug-induced hypersensitivity. J. Allergy Clin. Immunol. 2001; 108: 475–488
   PubMed Web of Science ®Google Scholar
• Guengerich F. P. Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem. Res. Toxicol. 1990; 3: 363–371
   PubMed Web of Science ®Google Scholar
• Guengerich F. P., Kim D. H., Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol. 1991; 4: 168–179
   PubMed Web of Science ®Google Scholar
• Ha-Duong N. T., Dijols S., Macherey A. C., Goldstein J. A., Dansette P. M., Mansuy D. Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. Biochemistry 2001; 40: 12112–12122
   PubMed Web of Science ®Google Scholar
• Halpert J. R. Structural basis of selective cytochrome P450 inhibition. Annu. Rev. Pharmacol. Toxicol. 1995; 35: 29–53
   PubMed Web of Science ®Google Scholar
• Halpert J. R., Guengerich F. P., Bend J. R., Correia M. A. Selective inhibitors of cytochromes P450. Toxicol. Appl. Pharmacol. 1994; 125: 163–175
   PubMed Web of Science ®Google Scholar
• Handley D. A., Magnetti A., Higgins A. J. Therapeutic advantages of third generation antihistamines. Expert Opin. Investig. Drugs 1998; 7: 1045–1054
   PubMedGoogle Scholar
• He K., Falick A. M., Chen B., Nilsson F., Correia M. A. Identification of the heme adduct and an active site peptide modified during mechanism-based inactivation of rat liver cytochrome P450 2B1 by secobarbital. Chem. Res. Toxicol. 1996; 9: 614–622
   PubMed Web of Science ®Google Scholar
• He K., Iyer K. R., Hayes R. N., Sinz M. W., Woolf T. F., Hollenberg P. F. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem. Res. Toxicol. 1998; 11: 252–259
   PubMed Web of Science ®Google Scholar
• He K., Woolf T. F., Hollenberg P. F. Mechanism-based inactivation of cytochrome P-450–3A4 by mifepristone (RU486). J. Pharmacol. Exp. Ther. 1999; 288: 791–797
   PubMed Web of Science ®Google Scholar
• Herman R. J. Drug interactions and the statins. CMAJ 1999; 161: 1281–1286
   PubMed Web of Science ®Google Scholar
• Holley A. E., Frater Y., Gibbs A. H., De Matteis F., Lamb J. H., Farmer P. B., Naylor S. Isolation of two N-monosubstituted protoporphyrins, bearing either the whole drug or a methyl group on the pyrrole nitrogen atom, from liver of mice given griseofulvin. Biochem. J. 1991; 274: 843–848
   PubMedGoogle Scholar
• Homberg J. C., Andre C., Abuaf N. A new anti-liver-kidney microsome antibody (anti-LKM2) in tienilic acid-induced hepatitis. Clin. Exp. Immunol. 1984; 55: 561–570
   PubMed Web of Science ®Google Scholar
• Jang G. R., Benet L. Z. Antiprogestin-mediated inactivation of cytochrome P450 3A4. Pharmacology 1998; 56: 150–157
   PubMed Web of Science ®Google Scholar
• Jean P., Lopez-Garcia P., Dansette P., Mansuy D., Goldstein J. L. Oxidation of tienilic acid by human yeast-expressed cytochromes P-450 2C8, 2C9, 2C18 and 2C19. Evidence that this drug is a mechanism-based inhibitor specific for cytochrome P-450 2C9. Eur. J. Biochem. 1996; 241: 797–804
   PubMedGoogle Scholar
• Jones D. R., Gorski J. C., Hamman M. A., Mayhew B. S., Rider S., Hall S. D. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J. Pharmacol. Exp. Ther. 1999; 290: 1116–1125
   PubMed Web of Science ®Google Scholar
• Kalgutkar A. S., Vaz A. D., Lame M. E., Henne K. R., Soglia J., Zhao S. X., Abramov Y. A., Lombardo F., Collin C., Hendsch Z. S., Hop C. E. Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4. Drug Metab. Dispos. 2005; 33: 243–253
   PubMed Web of Science ®Google Scholar
• Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov. 2005; 4: 489–499
   PubMed Web of Science ®Google Scholar
• Kassahun K., Pearson P. G., Tang W., McIntosh I., Leung K., Elmore C., Dean D., Wang R., Doss G., Baillie T. A. Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem. Res. Toxicol. 2001; 14: 62–70
   PubMed Web of Science ®Google Scholar
• Kenna J. G. Immunoallergic drug-induced hepatitis: lessons from halothane. J. Hepatol. 1997; 26: 5–12
   PubMedGoogle Scholar
• Kent U. M., Juschyshyn M. I., Hollenberg P. F. Mechanism-based inactivators as probes of cytochrome P450 structure and function. Curr. Drug Metab. 2001; 2: 215–243
   PubMed Web of Science ®Google Scholar
• Kent U. M., Mills D. E., Rajnarayanan R. V., Alworth W. L., Hollenberg P. F. Effect of 17-alpha-ethynylestradiol on activities of cytochrome P450 2B (P450 2B) enzymes: Characterization of inactivation of P450s 2B1 and 2B6 and identification of metabolites. J. Pharmacol. Exp. Ther. 2002; 300: 549–558
   PubMed Web of Science ®Google Scholar
• Khan K. K., He Y. Q., Correia M. A., Halpert J. R. Differential oxidation of mifepristone by cytochromes P450 3A4 and 3A5: Selective inactivation of P450 3A4. Drug Metab. Dispos. 2002; 30: 985–990
   PubMed Web of Science ®Google Scholar
• Khan K. K., He Y. Q., Domanski T. L., Halpert J. R. Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. Mol. Pharmacol. 2002; 61: 495–506
   PubMed Web of Science ®Google Scholar
• Kharasch E. D., Hankins D., Mautz D., Thummel K. E. Identification of the enzyme responsible for oxidative halothane metabolism: Implications for prevention of halothane hepatitis. Lancet 1996; 347: 1367–1371
   PubMed Web of Science ®Google Scholar
• Kimmett S. M., McNamee J. P., Denofreo R. T., Marks G. S. Evidence for mechanism-based inactivation of rat and chick embryo hepatic cytochrome P4501A and P4503A by dihydropyridines, sydnones, and dihydroquinolines. Biochem. Pharmacol. 1994; 47: 2069–2078
   Google Scholar
• Kivisto K. T., Neuvonen P. J., Klotz U. Inhibition of terfenadine metabolism. Pharmacokinetic and pharmacodynamic consequences. Clin. Pharmacokinet. 1994; 27: 1–5
   PubMedGoogle Scholar
• Knasmuller S., Parzefall W., Helma C., Kassie F., Ecker S., Schulte-Hermann R. Toxic effects of griseofulvin: Disease models, mechanisms, and risk assessment. Crit. Rev. Toxicol. 1997; 27: 495–537
   PubMed Web of Science ®Google Scholar
• Koenigs L. L., Peter R. M., Hunter A. P., Haining R. L., Rettie A. E., Friedberg T., Pritchard M. P., Shou M., Rushmore T. H., Trager W. F. Electrospray ionization mass spectrometric analysis of intact cytochrome P450: identification of tienilic acid adducts to P450 2C9. Biochemistry 1999; 38: 2312–2319
   PubMed Web of Science ®Google Scholar
• Koenigs L. L., Peter R. M., Thompson S. J., Rettie A. E., Trager W. F. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Drug Metab. Dispos. 1997; 25: 1407–1415
   PubMed Web of Science ®Google Scholar
• Koenigs L. L., Trager W. F. Mechanism-based inactivation of P450 2A6 by furanocoumarins. Biochemistry 1998; 37: 10047–10061
   PubMed Web of Science ®Google Scholar
• Koudriakova T., Iatsimirskaia E., Utkin I., Gangl E., Vouros P., Storozhuk E., Orza D., Marinina J., Gerber N. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: Mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab. Dispos. 1998; 26: 552–561
   PubMed Web of Science ®Google Scholar
• Krayenbuhl J. C., Vozeh S., Kondo-Oestreicher M., Dayer P. Drug–drug interactions of new active substances: mibefradil example. Eur. J. Clin. Pharmacol. 1999; 55: 559–565
   PubMed Web of Science ®Google Scholar
• Krieter P. A., van Dyke R. A. Cytochrome P-450 and halothane metabolism. Decrease in rat liver microsomal P-450 in vitro. Chem. Biol. Interact. 1983; 44: 219–235
   PubMed Web of Science ®Google Scholar
• Kumar S., Bandyopadhyay U. Free heme toxicity and its detoxification systems in human. Toxicol. Lett. 2005; 157: 175–188
   PubMed Web of Science ®Google Scholar
• Kunze K. L., Trager W. F. Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem. Res. Toxicol. 1993; 6: 649–656
   PubMed Web of Science ®Google Scholar
• Lavigne J. A., Nakatsu K., Marks G. S. Identification of human hepatic cytochrome P450 sources of N-alkylprotoporphyrin IX after interaction with porphyrinogenic xenobiotics, implications for detection of xenobiotic-induced porphyria in humans. Drug Metab. Dispos. 2002; 30: 788–794
   PubMed Web of Science ®Google Scholar
• Lecoeur S., Andre C., Beaune P. H. Tienilic acid-induced autoimmune hepatitis: anti-liver and-kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9. Mol. Pharmacol. 1996; 50: 326–333
   PubMed Web of Science ®Google Scholar
• Lecoeur S., Bonierbale E., Challine D., Gautier J. C., Valadon P., Dansette P. M., Catinot R., Ballet F., Mansuy D., Beaune P. H. Specificity of in vitro covalent binding of tienilic acid metabolites to human liver microsomes in relationship to the type of hepatotoxicity: Comparison with two directly hepatotoxic drugs. Chem. Res. Toxicol. 1994; 7: 434–442
   PubMed Web of Science ®Google Scholar
• Leeder J. S., Gaedigk A., Lu X., Cook V. A. Epitope mapping studies with human anti-cytochrome P450 3A antibodies. Mol. Pharmacol. 1996; 49: 234–243
   PubMed Web of Science ®Google Scholar
• Leeder J. S., Lu X., Timsit Y., Gaedigk A. Non-monooxygenase cytochromes P450 as potential human autoantigens in anticonvulsant hypersensitivity reactions. Pharmacogenetics 1998; 8: 211–225
   PubMedGoogle Scholar
• Leeder J. S., Riley R. J., Cook V. A., Spielberg S. P. Human anti-cytochrome P450 antibodies in aromatic anticonvulsant-induced hypersensitivity reactions. J. Pharmacol. Exp. Ther. 1992; 263: 360–367
   PubMed Web of Science ®Google Scholar
• Levy R. H., Thummel K. E., Trager W. F., Hansten P. D., Eichelbaum M. Metabolic drug interactions. Lippincott Williams & Wilkins, Philadelphia 2000
   Google Scholar
• Lightning L. K., Jones J. P., Friedberg T., Pritchard M. P., Shou M., Rushmore T. H., Trager W. F. Mechanism-based inactivation of cytochrome P450 3A4 by L-754,394. Biochemistry 2000; 39: 4276–4287
   PubMed Web of Science ®Google Scholar
• Lillibridge J. H., Liang B. H., Kerr B. M., Webber S., Quart B., Shetty B. V., Lee C. A. Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab. Dispos. 1998; 26: 609–616
   PubMed Web of Science ®Google Scholar
• Lim H. K., Duczak N., Jr, Brougham L., Elliot M., Patel K., Chan K. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6 and CYP1A2 in pooled human liver microsomes. Drug Metab. Dispos. 2005; 33: 1211–1219
   PubMed Web of Science ®Google Scholar
• Lin H. L., Kent U. M., Hollenberg P. F. Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: Evidence for heme destruction and covalent binding to protein. J. Pharmacol. Exp. Ther. 2002; 301: 160–167
   PubMed Web of Science ®Google Scholar
• Lin H. L., Kent U. M., Hollenberg P. F. The grapefruit juice effect is not limited to cytochrome P450 (P450) 3A4: Evidence for bergamottin-dependent inactivation, heme destruction, and covalent binding to protein in P450s 2B6 and 3A5. J. Pharmacol. Exp. Ther. 2005; 313: 154–164
   PubMed Web of Science ®Google Scholar
• Lindstrom T. D., Hanssen B. R., Wrighton S. A. Cytochrome P-450 complex formation by dirithromycin and other macrolides in rat and human livers. Antimicrob. Agents Chemother. 1993; 37: 265–269
   PubMed Web of Science ®Google Scholar
• Liu H., Baliga M., Baliga R. Effect of cytochrome P450 2E1 inhibitors on cisplatin-induced cytotoxicity to renal proximal tubular epithelial cells. Anticancer Res. 2002; 22: 863–868
   PubMed Web of Science ®Google Scholar
• Liu H., Baliga R. Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003; 63: 1687–1696
   PubMed Web of Science ®Google Scholar
• Lopez-Garcia M. P., Dansette P. M., Mansuy D. Thiophene derivatives as new mechanism-based inhibitors of cytochromes P-450: Inactivation of yeast-expressed human liver cytochrome P-450 2C9 by tienilic acid. Biochemistry 1994; 33: 166–175
   PubMed Web of Science ®Google Scholar
• Lopez Garcia M. P., Dansette P. M., Valadon P., Amar C., Beaune P. H., Guengerich F. P., Mansuy D. Human-liver cytochromes P-450 expressed in yeast as tools for reactive-metabolite formation studies. Oxidative activation of tienilic acid by cytochromes P-450 2C9 and 2C10. Eur. J. Biochem. 1993; 213: 223–232
   PubMedGoogle Scholar
• Lytton S. D., Berg U., Nemeth A., Ingelman-Sundberg M. Autoantibodies against cytochrome P450s in sera of children treated with immunosuppressive drugs. Clin. Exp. Immunol. 2002; 127: 293–302
   PubMed Web of Science ®Google Scholar
• Lytton S. D., Helander A., Zhang-Gouillon Z. Q., Stokkeland K., Bordone R., Arico S., Albano E., French S. W., Ingelman-Sundberg M. Autoantibodies against cytochromes P-4502E1 and P-4503A in alcoholics. Mol. Pharmacol. 1999; 55: 223–233
   PubMed Web of Science ®Google Scholar
• Ma B., Prueksaritanont T., Lin J. H. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab. Dispos. 2000; 28: 125–130
   PubMed Web of Science ®Google Scholar
• Malhotra S., Bailey D. G., Paine M. F., Watkins P. B. Seville orange juice–felodipine interaction: Comparison with dilute grapefruit juice and involvement of furocoumarins. Clin. Pharmacol. Ther. 2001; 69: 14–23
   PubMed Web of Science ®Google Scholar
• Manno M., Cazzaro S., Rezzadore M. The mechanism of the suicidal reductive inactivation of microsomal cytochrome P-450 by halothane. Arch. Toxicol. 1991; 65: 191–198
   PubMed Web of Science ®Google Scholar
• Manno M., De Matteis F., King L. J. The mechanism of the suicidal, reductive inactivation of microsomal cytochrome P-450 by carbon tetrachloride. Biochem. Pharmacol. 1988; 37: 1981–1990
   PubMed Web of Science ®Google Scholar
• Manno M., Ferrara R., Cazzaro S., Rigotti P., Ancona E. Suicidal inactivation of human cytochrome P-450 by carbon tetrachloride and halothane in vitro. Pharmacol. Toxicol. 1992; 70: 13–18
   PubMedGoogle Scholar
• Manns M. P., Obermayer-Straub P. Cytochromes P450 and uridine triphosphate-glucuronosyltransferases: Model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease. Hepatology 1997; 26: 1054–1066
   PubMed Web of Science ®Google Scholar
• Marini S., Longo V., Zaccaro C., De Matteis F., Gervasi P. G. Selective inactivation of rat and bovine olfactory cytochrome P450 by three haloethanes. Toxicol. Lett. 2001; 124: 83–90
   PubMed Web of Science ®Google Scholar
• Marks G. S., Allen D. T., Johnston C. T., Sutherland E. P., Nakatsu K., Whitney R. A. Suicidal destruction of cytochrome P-450 and reduction of ferrochelatase activity by 3,5-diethoxycarbonyl-1,4-dihydro-2,4,6-trimethylpyridine and its analogues in chick embryo liver cells. Mol. Pharmacol. 1985; 27: 459–465
   Google Scholar
• Marks G. S., Goldman D. R., McCluskey S. A., Sutherland E. P., Lyon M. E. The effects of dihydropyridine calcium antagonists on heme biosynthesis in chick embryo liver cell culture. Can. J. Physiol. Pharmacol. 1986; 64: 438–443
   PubMed Web of Science ®Google Scholar
• Marks G. S., McCluskey S. A., Mackie J. E., Riddick D. S., James C. A. Disruption of hepatic heme biosynthesis after interaction of xenobiotics with cytochrome P-450. FASEB J. 1988; 2: 2774–2783
   PubMed Web of Science ®Google Scholar
• Martin J. L., Keegan M. T., Vasdev G. M., Nyberg S. L., Bourdi M., Pohl L. R., Plevak D. J. Fatal hepatitis associated with isoflurane exposure and CYP2A6 autoantibodies. Anesthesiology 2001; 95: 551–553
   Google Scholar
• Masubuchi Y., Horie T. Dihydralazine-induced inactivation of cytochrome P450 enzymes in rat liver microsomes. Drug Metab. Dispos. 1998; 26: 338–342
   PubMed Web of Science ®Google Scholar
• Masubuchi Y., Horie T. Mechanism-based inactivation of cytochrome P450s 1A2 and 3A4 by dihydralazine in human liver microsomes. Chem. Res. Toxicol. 1999; 12: 1028–1032
   PubMed Web of Science ®Google Scholar
• Masubuchi Y., Nakano T., Ose A., Horie T. Differential selectivity in carbamazepine-induced inactivation of cytochrome P450 enzymes in rat and human liver. Arch. Toxicol. 2001; 75: 538–543
   PubMed Web of Science ®Google Scholar
• Masubuchi Y., Ose A., Horie T. Diclofenac-induced inactivation of CYP3A4 and its stimulation by quinidine. Drug Metab. Dispos. 2002; 30: 1143–1148
   PubMed Web of Science ®Google Scholar
• Matzinger P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 1994; 12: 991–1045
   PubMed Web of Science ®Google Scholar
• Mayhew B. S., Jones D. R., Hall S. D. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab. Dispos. 2000; 28: 1031–1037
   PubMed Web of Science ®Google Scholar
• McConn D. J., 2nd, Lin Y. S., Allen K., Kunze K. L., Thummel K. E. Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs. Drug Metab. Dispos. 2004; 32: 1083–1091
   PubMed Web of Science ®Google Scholar
• McNamee J. P., Jurima-Romet M., Kobus S. M., Marks G. S. cDNA-expressed human cytochrome P450 isozymes. Inactivation by porphyrinogenic xenobiotics. Drug Metab. Dispos. 1997; 25: 437–441
   PubMed Web of Science ®Google Scholar
• McNamee J. P., Marks G. S. Cytochrome P4503A is the major source of N-vinylprotoporphyrin IX formation after administration of 3-[2-(2,4,6-trimethylphenyl)thioethyl]-4-methylsydnone to untreated and dexamethasone-pretreated rats. Drug Metab. Dispos. 1996; 24: 872–878
   PubMedGoogle Scholar
• Michalets E. L., Williams C. R. Drug interactions with cisapride: clinical implications. Clin. Pharmacokinet. 2000; 39: 49–75
   PubMed Web of Science ®Google Scholar
• Minoda Y., Kharasch E. D. Halothane-dependent lipid peroxidation in human liver microsomes is catalyzed by cytochrome P4502A6 (CYP2A6). Anesthesiology 2001; 95: 509–514
   PubMedGoogle Scholar
• Mullins M. E., Horowitz B. Z., Linden D. H., Smith G. W., Norton R. L., Stump J. Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers. JAMA 1998; 280: 157–158
   PubMed Web of Science ®Google Scholar
• Munns A. J., De Voss J. J., Hooper W. D., Dickinson R. G., Gillam E. M. Bioactivation of phenytoin by human cytochrome P450: Characterization of the mechanism and targets of covalent adduct formation. Chem. Res. Toxicol. 1997; 10: 1049–1058
   PubMed Web of Science ®Google Scholar
• Murray M. Mechanisms of the inhibition of cytochrome P-450-mediated drug oxidation by therapeutic agents. Drug Metab. Rev. 1987; 18: 55–81
   PubMed Web of Science ®Google Scholar
• Murray M. Drug-mediated inactivation of cytochrome P450. Clin. Exp. Pharmacol. Physiol. 1997; 24: 465–470
   PubMed Web of Science ®Google Scholar
• Murray M., Reidy G. F. Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. Pharmacol. Rev. 1990; 42: 85–101
   PubMed Web of Science ®Google Scholar
• Nakahira K., Takahashi T., Shimizu H., Maeshima K., Uehara K., Fujii H., Nakatsuka H., Yokoyama M., Akagi R., Morita K. Protective role of heme oxygenase-1 induction in carbon tetrachloride-induced hepatotoxicity. Biochem. Pharmacol. 2003; 66: 1091–1105
   PubMedGoogle Scholar
• Nataf J., Bernuau J., Larrey D., Guillin M., Rueff B., Benhamou J.-P. A new anti-liver microsome antibody: a specific marker of dihydralazine-induced hepatitis. Gastroenterology 1986; 90: 1751
   Web of Science ®Google Scholar
• Newton D. J., Wang R. W., Lu A. Y. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. 1995; 23: 154–158
   PubMed Web of Science ®Google Scholar
• O'Donnell J. P., Dalvie D. K., Kalgutkar A. S., Obach R. S. Mechanism-based inactivation of human recombinant P450 2C9 by the nonsteroidal anti-inflammatory drug suprofen. Drug Metab. Dispos. 2003; 31: 1369–1377
   PubMed Web of Science ®Google Scholar
• Obermayer-Straub P., Manns M. P. Cytochromes P450 and UDP-glucuronosyl-transferases as hepatocellular autoantigens. Baillieres Clin. Gastroenterol. 1996; 10: 501–532
   PubMed Web of Science ®Google Scholar
• Odaka Y., Takahashi T., Yamasaki A., Suzuki T., Fujiwara T., Yamada T., Hirakawa M., Fujita H., Ohmori E., Akagi R. Prevention of halothane-induced hepatotoxicity by hemin pretreatment: protective role of heme oxygenase-1 induction. Biochem. Pharmacol. 2000; 59: 871–880
   Google Scholar
• Ohyama K., Nakajima M., Suzuki M., Shimada N., Yamazaki H., Yokoi T. Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: Prediction of in vivo drug interactions. Br. J. Clin. Pharmacol. 2000; 49: 244–253
   PubMed Web of Science ®Google Scholar
• Ono S., Hatanaka T., Hotta H., Satoh T., Gonzalez F. J., Tsutsui M. Specificity of substrate and inhibitor probes for cytochrome P450s: Evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 1996; 26: 681–693
   PubMed Web of Science ®Google Scholar
• Oritz de Montellano P. R., Correia M. A. Suicidal destruction of cytochrome P-450 during oxidative drug metabolism. Annu. Rev. Pharmacol. Toxicol. 1983; 23: 481–503
   Google Scholar
• Ortiz de Montellano P. R., Beilan H. S., Kunze K. L. N-Alkylprotoporphyrin IX formation in 3,5-dicarbethoxy-1,4-dihydrocollidine-treated rats. Transfer of the alkyl group from the substrate to the porphyrin. J. Biol. Chem. 1981; 256: 6708–6713
   PubMed Web of Science ®Google Scholar
• Ortiz de Montellano P. R., Grab L. A. Inactivation of cytochrome P-450 during catalytic oxidation of a 3-[(arylthio)ethyl]sydnone: N-Vinyl heme formation via insertion into the iron–nitrogen bond. J. Aml. Chem. Soc. 1986; 108: 5584–5589
   Google Scholar
• Ortiz de Montellano P. R., Komives E. A. Branchpoint for heme alkylation and metabolite formation in the oxidation of arylacetylenes by cytochrome P-450. J. Biol. Chem. 1985; 260: 3330–3336
   PubMed Web of Science ®Google Scholar
• Ortiz de Montellano P. R., Mico B. A. Destruction of cytochrome P-450 by ethylene and other olefins. Mol. Pharmacol. 1980; 18: 128–135
   PubMed Web of Science ®Google Scholar
• Paakkari I. Cardiotoxicity of new antihistamines and cisapride. Toxicol. Lett. 2002; 127: 279–284
   PubMed Web of Science ®Google Scholar
• Paris D. G., Parente T. F., Bruschetta H. R., Guzman E., Niarchos A. P. Torsades de pointes induced by erythromycin and terfenadine. Am. J. Emerg. Med. 1994; 12: 636–638
   PubMed Web of Science ®Google Scholar
• Park B. K., Pirmohamed M., Kitteringham N. R. Role of drug disposition in drug hypersensitivity: A chemical, molecular, and clinical perspective. Chem. Res. Toxicol. 1998; 11: 969–988
   PubMed Web of Science ®Google Scholar
• Patsalos P. N., Froscher W., Pisani F., van Rijn C. M. The importance of drug interactions in epilepsy therapy. Epilepsia 2002; 43: 365–385
   PubMed Web of Science ®Google Scholar
• Periti P., Mazzei T., Mini E., Novelli A. Pharmacokinetic drug interactions of macrolides. Clin. Pharmacokinet. 1992; 23: 106–131
   PubMed Web of Science ®Google Scholar
• Pirmohamed M., Naisbitt D. J., Gordon F., Park B. K. The danger hypothesis—Potential role in idiosyncratic drug reactions. Toxicology 2002; 181–182: 55–63
   PubMed Web of Science ®Google Scholar
• Plosch T., Bloks V. W., Baller J. F., Havinga R., Verkade H. J., Jansen P. L., Kuipers F. Mdr P-glycoproteins are not essential for biliary excretion of the hydrophobic heme precursor protoporphyrin in a griseofulvin-induced mouse model of erythropoietic protoporphyria. Hepatology 2002; 35: 299–306
   PubMed Web of Science ®Google Scholar
• Pohl L. R., Kenna J. G., Satoh H., Christ D., Martin J. L. Neoantigens associated with halothane hepatitis. Drug Metab. Rev. 1989; 20: 203–217
   PubMed Web of Science ®Google Scholar
• Pohl L. R., Satoh H., Christ D. D., Kenna J. G. The immunologic and metabolic basis of drug hypersensitivities. Annu. Rev. Pharmacol. Toxicol. 1988; 28: 367–387
   PubMed Web of Science ®Google Scholar
• Polasek T. M., Elliot D. J., Lewis B. C., Miners J. O. Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. J. Pharmacol. Exp. Ther. 2004; 311: 996–1007
   PubMed Web of Science ®Google Scholar
• Pons C., Dansette P. M., Amar C., Jaouen M., Wolf C. R., Gregeois J., Homberg J. C., Mansuy D. Detection of human hepatitis anti-liver kidney microsomes (LKM2) autoantibodies on rat liver sections is predominantly due to reactivity with rat liver P-450 IIC11. J. Pharmacol. Exp. Ther. 1991; 259: 1328–1334
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T., Ma B., Tang C., Meng Y., Assang C., Lu P., Reider P. J., Lin J. H., Baillie T. A. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: An in vitro investigation with human liver preparations. Br. J. Clin. Pharmacol. 1999; 47: 291–298
   PubMed Web of Science ®Google Scholar
• Racha J. K., Rettie A. E., Kunze K. L. Mechanism-based inactivation of human cytochrome P450 1A2 by furafylline: Detection of a 1:1 adduct to protein and evidence for the formation of a novel imidazomethide intermediate. Biochemistry 1998; 37: 7407–7419
   PubMed Web of Science ®Google Scholar
• Rando R. R. Mechanism-based enzyme inactivators. Pharmacol. Rev. 1984; 36: 111–142
   PubMed Web of Science ®Google Scholar
• Rasmussen B. B., Maenpaa J., Pelkonen O., Loft S., Poulsen H. E., Lykkesfeldt J., Brosen K. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: Potent inhibition by fluvoxamine. Br. J. Clin. Pharmacol. 1995; 39: 151–159
   PubMed Web of Science ®Google Scholar
• Richter T., Murdter T. E., Heinkele G., Pleiss J., Tatzel S., Schwab M., Eichelbaum M., Zanger U. M. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J. Pharmacol. Exp. Ther. 2004; 308: 189–197
   PubMed Web of Science ®Google Scholar
• Riddick D. S., Marks G. S. Irreversible binding of heme to microsomal protein during inactivation of cytochrome P450 by 4-alkyl analogues of 3,5-diethoxycarbonyl-1,4-dihydro-2,4,6-trimethylpyridine. Biochem. Pharmacol. 1990; 40: 1915–1921
   Google Scholar
• Riddick D. S., Park S. S., Gelboin H. V., Marks G. S. Effects of a series of 4-alkyl analogues of 3,5-diethoxycarbonyl-1,4-dihydro-2,4,6-trimethylpyridine on the major inducible cytochrome P-450 isozymes of rat liver. Mol. Pharmacol. 1989; 35: 626–634
   Google Scholar
• Robin M. A., Le Roy M., Descatoire V., Pessayre D. Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis. J. Hepatol. 1997; 26: 23–30
   PubMedGoogle Scholar
• Robin M. A., Maratrat M., Le Roy M., Le Breton F. P., Bonierbale E., Dansette P., Ballet F., Mansuy D., Pessayre D. Antigenic targets in tienilic acid hepatitis. Both cytochrome P450 2C11 and 2C11-tienilic acid adducts are transported to the plasma membrane of rat hepatocytes and recognized by human sera. J. Clin. Invest. 1996; 98: 1471–1480
   PubMed Web of Science ®Google Scholar
• Rodrigues A. D. Drug–drug interactions. Marcel Dekker, New York 2002
   Google Scholar
• Safirstein R., Winston J., Goldstein M., Moel D., Dikman S., Guttenplan J. Cisplatin nephrotoxicity. Am. J. Kidney Dis. 1986; 8: 356–367
   PubMed Web of Science ®Google Scholar
• Sahali-Sahly Y., Balani S. K., Lin J. H., Baillie T. A. In vitro studies on the metabolic activation of the furanopyridine L-754,394, a highly potent and selective mechanism-based inhibitor of cytochrome P450 3A4. Chem. Res. Toxicol. 1996; 9: 1007–1012
   PubMed Web of Science ®Google Scholar
• Sai Y., Dai R., Yang T. J., Krausz K. W., Gonzalez F. J., Gelboin H. V., Shou M. Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450. Xenobiotica 2000; 30: 327–343
   PubMed Web of Science ®Google Scholar
• Salonpaa P., Kottari S., Pelkonen O., Raunio H. Regulation of CYP 2 A 5 induction by porphyrinogenic agents in mouse primary hepatocytes. Naunyn. Schmiedebergs Arch. Pharmacol. 1997; 355: 8–13
   Google Scholar
• Salonpaa P., Krause K., Pelkonen O., Raunio H. Up-regulation of CYP2A5 expression by porphyrinogenic agents in mouse liver. Naunyn. Schmiedebergs Arch. Pharmacol. 1995; 351: 446–452
   PubMed Web of Science ®Google Scholar
• Schaaf G. J., Maas R. F., de Groene E. M., Fink-Gremmels J. Management of oxidative stress by heme oxygenase-1 in cisplatin-induced toxicity in renal tubular cells. Free Radical Res. 2002; 36: 835–843
   PubMed Web of Science ®Google Scholar
• Schmiedlin-Ren P., Edwards D. J., Fitzsimmons M. E., He K., Lown K. S., Woster P. M., Rahman A., Thummel K. E., Fisher J. M., Hollenberg P. F., Watkins P. B. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab. Dispos. 1997; 25: 1228–1233
   PubMed Web of Science ®Google Scholar
• Screnci D., McKeage M. J. Platinum neurotoxicity: Clinical profiles, experimental models and neuroprotective approaches. J. Inorg. Biochem. 1999; 77: 105–110
   PubMed Web of Science ®Google Scholar
• Seguin B., Uetrecht J. The danger hypothesis applied to idiosyncratic drug reactions. Curr. Opin. Allergy Clin. Immunol. 2003; 3: 235–242
   PubMed Web of Science ®Google Scholar
• Shear N. H., Spielberg S. P. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J. Clin. Invest. 1988; 82: 1826–1832
   PubMed Web of Science ®Google Scholar
• Shiraishi F., Curtis L. M., Truong L., Poss K., Visner G. A., Madsen K., Nick H. S., Agarwal A. Heme oxygenase-1 gene ablation or expression modulates cisplatin-induced renal tubular apoptosis. Am. J. Physiol. Renal Physiol. 2000; 278: F726–736
   PubMed Web of Science ®Google Scholar
• Silverman R. B. Mechanism-based enzyme inactivation: Chemistry and Enzymology. CRC Press, Boca Raton, FL 1988; Vol. 1
   Google Scholar
• Simonsen U. Interactions between drugs for erectile dysfunction and drugs for cardiovascular disease. Int. J. Impot. Res. 2002; 14: 178–188
   PubMed Web of Science ®Google Scholar
• Smith A. G., De Matteis F. Drugs and the hepatic porphyrias. Clin. Haematol. 1980; 9: 399–425
   PubMedGoogle Scholar
• Spina E., Pisani F., Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clin. Pharmacokinet. 1996; 31: 198–214
   PubMed Web of Science ®Google Scholar
• Spracklin D. K., Hankins D. C., Fisher J. M., Thummel K. E., Kharasch E. D. Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism in vitro. J. Pharmacol. Exp. Ther. 1997; 281: 400–411
   PubMed Web of Science ®Google Scholar
• Spracklin D. K., Thummel K. E., Kharasch E. D. Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4. Drug Metab. Dispos. 1996; 24: 976–983
   PubMed Web of Science ®Google Scholar
• Sridar C., Kent U. M., Notley L. M., Gillam E. M., Hollenberg P. F. Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J. Pharmacol. Exp. Ther. 2002; 301: 945–952
   PubMed Web of Science ®Google Scholar
• Sutherland E. P., Marks G. S., Grab L. A., Ortiz de Montellano P. R. Porphyrinogenic activity and ferrochelatase-inhibitory activity of sydnones in chick embryo liver cells. FEBS Lett. 1986; 197: 17–20
   Google Scholar
• Tanaka E. Clinically significant pharmacokinetic drug interactions with benzodiazepines. J. Clin. Pharm. Ther. 1999; 24: 347–355
   PubMed Web of Science ®Google Scholar
• Tassaneeyakul W., Birkett D. J., Veronese M. E., McManus M. E., Tukey R. H., Miners J. O. Direct characterization of the selectivity of furafylline as an inhibitor of human cytochromes P450 1A1 and 1A2. Pharmacogenetics 1994; 4: 281–284
   PubMedGoogle Scholar
• Tassaneeyakul W., Guo L. Q., Fukuda K., Ohta T., Yamazoe Y. Inhibition selectivity of grapefruit juice components on human cytochromes P450. Arch. Biochem. Biophys. 2000; 378: 356–363
   PubMed Web of Science ®Google Scholar
• Tephly T. R., Black K. A., Green M. D., Coffman B. L., Dannan G. A., Guengerich F. P. Effect of the suicide substrate 3,5-diethoxycarbonyl-2,6-dimethyl-4-ethyl-1,4-dihydropyridine on the metabolism of xenobiotics and on cytochrome P-450 apoproteins. Mol. Pharmacol. 1986; 29: 81–87
   PubMed Web of Science ®Google Scholar
• Tephly T. R., Coffman B. L., Ingall G., Ziet-Har M. S., Goff H. M., Tabba H. D., Smith K. M. Identification of N-methylprotoporphyrin IX in livers of untreated mice and mice treated with 3,5-diethoxycarbonyl-1,4-dihydrocollidine: Source of the methyl group. Arch. Biochem. Biophys. 1981; 212: 120–126
   PubMed Web of Science ®Google Scholar
• Tephly T. R., Gibbs A. H., De Matteis F. Studies on the mechanism of experimental porphyria produced by 3,5-diethoxycarbonyl-1,4-dihydrocollidine. Role of a porphyrin-like inhibitor of protohaem ferro-lyase. Biochem. J. 1979; 180: 241–244
   PubMed Web of Science ®Google Scholar
• Thummel K. E., Wilkinson G. R. In vitro and in vivo drug interactions involving human CYP3A. Annu. Rev. Pharmacol. Toxicol. 1998; 38: 389–430
   PubMed Web of Science ®Google Scholar
• Tinel M., Belghiti J., Descatoire V., Amouyal G., Letteron P., Geneve J., Larrey D., Pessayre D. Inactivation of human liver cytochrome P-450 by the drug methoxsalen and other psoralen derivatives. Biochem. Pharmacol. 1987; 36: 951–955
   PubMed Web of Science ®Google Scholar
• Uetrecht J. P. New concepts in immunology relevant to idiosyncratic drug reactions: The “danger hypothesis” and innate immune system. Chem. Res. Toxicol. 1999; 12: 387–395
   PubMed Web of Science ®Google Scholar
• Uno S., Dalton T. P., Sinclair P. R., Gorman N., Wang B., Smith A. G., Miller M. L., Shertzer H. G., Nebert D. W. Cyp1a1(-/-) male mice: Protection against high-dose TCDD-induced lethality and wasting syndrome, and resistance to intrahepatocyte lipid accumulation and uroporphyria. Toxicol. Appl. Pharmacol. 2004; 196: 410–421
   PubMed Web of Science ®Google Scholar
• Upton R. A. Pharmacokinetic interactions between theophylline and other medication (Part I). Clin. Pharmacokinet. 1991; 20: 66–80
   PubMed Web of Science ®Google Scholar
• Urban G., Speerschneider P., Dekant W. Metabolism of the chlorofluorocarbon substitute 1,1-dichloro-2,2,2-trifluoroethane by rat and human liver microsomes: the role of cytochrome P450 2E1. Chem. Res. Toxicol. 1994; 7: 170–176
   PubMed Web of Science ®Google Scholar
• van d en, Brekel A. M., Harrington L. Toxic effects of theophylline caused by fluvoxamine. CMAJ 1994; 151: 1289–1290
   Google Scholar
• Venkatakrishnan K., von Moltke L. L., Obach R. S., Greenblatt D. J. Drug metabolism and drug interactions: Application and clinical value of in vitro models. Curr. Drug Metab. 2003; 4: 423–459
   PubMed Web of Science ®Google Scholar
• Vergani D., Mieli-Vergani G., Alberti A., Neuberger J., Eddleston A. L., Davis M., Williams R. Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N. Engl. J. Med. 1980; 303: 66–71
   PubMed Web of Science ®Google Scholar
• Vidali M., Stewart S. F., Rolla R., Daly A. K., Chen Y., Mottaran E., Jones D. E., Leathart J. B., Day C. P., Albano E. Genetic and epigenetic factors in autoimmune reactions toward cytochrome P4502E1 in alcoholic liver disease. Hepatology 2003; 37: 410–419
   PubMed Web of Science ®Google Scholar
• von Rosensteil N. A., Adam D. Macrolide antibacterials. Drug interactions of clinical significance. Drug Safety 1995; 13: 105–122
   PubMed Web of Science ®Google Scholar
• Voorman R. L., Maio S. M., Payne N. A., Zhao Z., Koeplinger K. A., Wang X. Microsomal metabolism of delavirdine: Evidence for mechanism-based inactivation of human cytochrome P450 3A. J. Pharmacol. Exp. Ther. 1998; 287: 381–388
   PubMed Web of Science ®Google Scholar
• Wagener F. A., Volk H. D., Willis D., Abraham N. G., Soares M. P., Adema G. J., Figdor C. G. Different faces of the heme–heme oxygenase system in inflammation. Pharmacol. Rev. 2003; 55: 551–571
   PubMed Web of Science ®Google Scholar
• Wang Y. H., Jones D. R., Hall S. D. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab. Dispos. 2004; 32: 259–266
   PubMed Web of Science ®Google Scholar
• Wang Y. H., Jones D. R., Hall S. D. Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab. Dispos. 2005; 33: 664–671
   PubMed Web of Science ®Google Scholar
• Weber L. W., Boll M., Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: Carbon tetrachloride as a toxicological model. Crit. Rev. Toxicol. 2003; 33: 105–136
   PubMed Web of Science ®Google Scholar
• Welker H. A., Wiltshire H., Bullingham R. Clinical pharmacokinetics of mibefradil. Clin. Pharmacokinet. 1998; 35: 405–423
   PubMed Web of Science ®Google Scholar
• Westphal J. F. Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: An update focused on clarithromycin, azithromycin and dirithromycin. Br. J. Clin. Pharmacol. 2000; 50: 285–295
   PubMed Web of Science ®Google Scholar
• Williams D., Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin. Pharmacokinet. 2002; 41: 343–370
   PubMed Web of Science ®Google Scholar
• Williams M. T., Simonet L. Effects of griseofulvin on enzymes associated with phase I and II of drug metabolism. Biochem. Pharmacol. 1986; 35: 2630–2632
   PubMedGoogle Scholar
• Wolkenstein P., Tan C., Lecoeur S., Wechsler J., Garcia-Martin N., Charue D., Bagot M., Beaune P. Covalent binding of carbamazepine reactive metabolites to P450 isoforms present in the skin. Chem. Biol. Interact. 1998; 113: 39–50
   PubMed Web of Science ®Google Scholar
• Wong S. G., Kobus S. M., McNamee J. P., Marks G. S. Gender differences in N-alkyl protoporphyrin IX production in rats after the administration of porphyrinogenic xenobiotics. Drug Metab. Dispos. 1998; 26: 739–744
   PubMedGoogle Scholar
• Wong S. G., Lin E. H., Marks G. S. Cytochrome CYP sources of N-alkylprotoporphyrin IX after administration of porphyrinogenic xenobiotics to rats. Drug Metab. Dispos. 1999; 27: 960–965
   PubMedGoogle Scholar
• Woosley R. L. Cardiac actions of antihistamines. Annu. Rev. Pharmacol. Toxicol. 1996; 36: 233–252
   PubMed Web of Science ®Google Scholar
• Yamasaki A., Takahashi T., Suzuki T., Fujiwara T., Hirakawa M., Ohmori E., Akagi R. Differential effects of isoflurane and halothane on the induction of heat shock proteins. Biochem. Pharmacol. 2001; 62: 375–382
   PubMedGoogle Scholar
• Yao C., Kunze K. L., Kharasch E. D., Wang Y., Trager W. F., Ragueneau I., Levy R. H. Fluvoxamine-theophylline interaction: Gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. Clin. Pharmacol. Ther. 2001; 70: 415–424
   PubMed Web of Science ®Google Scholar
• Yeo K. R., Yeo W. W. Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. Br. J. Clin. Pharmacol. 2001; 51: 461–470
   PubMed Web of Science ®Google Scholar
• Yuan R., Flockhart D. A., Balian J. D. Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam. J. Clin. Pharmacol. 1999; 39: 1109–1125
   PubMed Web of Science ®Google Scholar
• Zhao X. J., Jones D. R., Wang Y. H., Grimm S. W., Hall S. D. Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites. Xenobiotica 2002; 32: 863–878
   PubMed Web of Science ®Google Scholar
• Zhou S., Chan E., Lim L. Y., Boelsterli U. A., Li S. C., Wang J., Zhang Q., Huang M., Xu A. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr. Drug Metab. 2004; 5: 415–442
   PubMed Web of Science ®Google Scholar
• Zhou S., Yung Chan S., Cher Goh B., Chan E., Duan W., Huang M., McLeod H. L. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet. 2005; 44: 279–304
   PubMed Web of Science ®Google Scholar